LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients
LifeMD has announced plans to expand access to Wegovy® (semaglutide) through NovoCare® Pharmacy for cash-pay patients. The company will offer the FDA-approved weight loss medication at a reduced self-pay cost of $499 per month, including home delivery.
Through their virtual care platform, LifeMD provides a comprehensive weight management program featuring:
- Virtual consultations
- Lab testing
- Diet and lifestyle support
- Prescriptions for anti-obesity medications including GLP-1s
The integration with NovoCare® Pharmacy allows direct access to all FDA-approved dose strengths of Wegovy®, which is notably the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. The service targets uninsured patients or those whose insurance doesn't cover prescription weight-loss medications.
LifeMD ha annunciato l'espansione dell'accesso a Wegovy® (semaglutide) tramite la farmacia NovoCare® per i pazienti che pagano in contanti. L'azienda offrirà il farmaco per la perdita di peso approvato dalla FDA a un costo ridotto di 499 dollari al mese, con consegna a domicilio inclusa.
Attraverso la loro piattaforma di assistenza virtuale, LifeMD propone un programma completo di gestione del peso che include:
- Consultazioni virtuali
- Analisi di laboratorio
- Supporto dietetico e per lo stile di vita
- Prescrizioni per farmaci anti-obesità, inclusi i GLP-1
L'integrazione con la farmacia NovoCare® consente l'accesso diretto a tutte le dosi approvate dalla FDA di Wegovy®, che rappresenta la prima terapia GLP-1 approvata negli Stati Uniti sia per la gestione cronica del peso sia per la riduzione del rischio cardiovascolare negli adulti con obesità. Il servizio è rivolto a pazienti non assicurati o a chi ha una copertura assicurativa che non include farmaci per la perdita di peso su prescrizione.
LifeMD ha anunciado planes para ampliar el acceso a Wegovy® (semaglutida) a través de la farmacia NovoCare® para pacientes que pagan en efectivo. La empresa ofrecerá el medicamento para la pérdida de peso aprobado por la FDA a un costo reducido de 499 dólares al mes, con entrega a domicilio incluida.
A través de su plataforma de atención virtual, LifeMD ofrece un programa integral de manejo de peso que incluye:
- Consultas virtuales
- Pruebas de laboratorio
- Apoyo en dieta y estilo de vida
- Prescripciones para medicamentos antiobesidad, incluidos los GLP-1
La integración con la farmacia NovoCare® permite el acceso directo a todas las dosis aprobadas por la FDA de Wegovy®, que es notablemente la primera terapia GLP-1 aprobada en Estados Unidos tanto para el manejo crónico del peso como para la reducción del riesgo cardiovascular en adultos con obesidad. El servicio está dirigido a pacientes sin seguro o cuyos seguros no cubren medicamentos para la pérdida de peso con receta.
LifeMD는 현금 결제 환자를 위해 NovoCare® 약국을 통해 Wegovy® (세마글루타이드) 접근성을 확대할 계획을 발표했습니다. 이 회사는 FDA 승인 체중 감량 약물을 월 499달러의 할인된 자비 부담 비용으로 제공하며, 가정 배달도 포함됩니다.
LifeMD의 가상 진료 플랫폼을 통해 다음과 같은 포괄적인 체중 관리 프로그램을 제공합니다:
- 가상 상담
- 실험실 검사
- 식단 및 생활 습관 지원
- GLP-1을 포함한 항비만 약물 처방
NovoCare® 약국과의 통합으로 Wegovy®의 모든 FDA 승인 용량에 직접 접근할 수 있으며, 이는 미국에서 만성 체중 관리 및 비만 성인 대상 심혈관 위험 감소를 위한 최초의 GLP-1 치료제입니다. 이 서비스는 보험이 없거나 보험이 처방 체중 감량 약물을 포함하지 않는 환자를 대상으로 합니다.
LifeMD a annoncé son intention d'élargir l'accès à Wegovy® (sémaglutide) via la pharmacie NovoCare® pour les patients payant en espèces. L'entreprise proposera ce médicament amaigrissant approuvé par la FDA à un tarif réduit de 499 dollars par mois, livraison à domicile comprise.
Grâce à leur plateforme de soins virtuels, LifeMD offre un programme complet de gestion du poids comprenant :
- Consultations virtuelles
- Analyses de laboratoire
- Soutien diététique et mode de vie
- Prescriptions de médicaments anti-obésité, y compris les GLP-1
L'intégration avec la pharmacie NovoCare® permet un accès direct à toutes les doses de Wegovy® approuvées par la FDA, qui est la première thérapie GLP-1 aux États-Unis approuvée à la fois pour la gestion chronique du poids et la réduction du risque cardiovasculaire chez les adultes obèses. Ce service cible les patients non assurés ou dont l'assurance ne couvre pas les médicaments amaigrissants sur ordonnance.
LifeMD hat Pläne angekündigt, den Zugang zu Wegovy® (Semaglutid) über die NovoCare® Apotheke für Selbstzahler zu erweitern. Das Unternehmen bietet das von der FDA zugelassene Medikament zur Gewichtsreduktion zu einem reduzierten Selbstzahlerpreis von 499 US-Dollar pro Monat inklusive Hauslieferung an.
Über ihre virtuelle Betreuungsplattform bietet LifeMD ein umfassendes Programm zur Gewichtskontrolle mit:
- Virtuellen Konsultationen
- Labortests
- Ernährungs- und Lebensstilunterstützung
- Verschreibungen für Anti-Adipositas-Medikamente, einschließlich GLP-1
Die Integration mit der NovoCare® Apotheke ermöglicht den direkten Zugang zu allen von der FDA zugelassenen Dosierungsstärken von Wegovy®, das als erste GLP-1-Therapie in den USA sowohl für das chronische Gewichtsmanagement als auch zur Reduzierung des kardiovaskulären Risikos bei adipösen Erwachsenen zugelassen ist. Der Service richtet sich an nicht versicherte Patienten oder solche, deren Versicherung verschreibungspflichtige Medikamente zur Gewichtsreduktion nicht abdeckt.
- Integration with NovoCare Pharmacy expands direct access to Wegovy, a high-demand GLP-1 medication
- Reduced self-pay cost at $499 per month makes treatment more accessible, potentially increasing customer base
- Company has 50-state affiliated medical group and national diagnostic lab partnerships
- Weight management program is one of the fastest-growing cash-pay offerings nationally
- Platform offers comprehensive services including virtual consultations, lab testing, and prescriptions in one place
- Cash-pay model may limit market reach compared to insurance-covered alternatives
- Dependence on single drug manufacturer (Novo Nordisk) for key product offering
- Competitive market space with other telehealth providers potentially offering similar services
Insights
LifeMD's Wegovy integration strengthens their position in the growing GLP-1 weight management market while creating a new recurring revenue stream.
LifeMD's integration with NovoCare Pharmacy to offer Wegovy (semaglutide) represents a strategic expansion of their telehealth weight management program. This move positions the company to capture market share in the rapidly growing GLP-1 therapeutics space.
The offering creates a streamlined path for cash-pay patients to access all FDA-approved doses of Wegovy at
What makes this particularly noteworthy is that Wegovy is the first GLP-1 therapy approved in the US with the dual indication for chronic weight management and cardiovascular risk reduction in adults with obesity. This expanded label increases its clinical value proposition.
LifeMD describes their weight management program as "one of the fastest-growing cash-pay offerings in the country," suggesting this segment is already performing well for the company. The integration adds a potential recurring revenue stream, as weight management typically requires ongoing medication, creating long-term customer relationships.
By embedding Wegovy access directly into their platform, LifeMD removes friction from the patient journey while potentially increasing retention rates within their ecosystem. Their vertically integrated infrastructure—including a 50-state affiliated medical group and national diagnostic lab partnerships—provides the operational framework needed to scale this offering effectively.
LifeMD's platform integration with NovoCare Pharmacy creates a seamless end-to-end digital experience for weight management patients.
LifeMD's integration with NovoCare Pharmacy represents a significant advancement in platform connectivity within the digital health ecosystem. By embedding direct access to Wegovy within their telehealth platform, LifeMD is eliminating traditional handoff friction between prescription and fulfillment—a pain point that often leads to patient drop-off.
The announcement highlights LifeMD's vertically integrated infrastructure, which includes a 50-state affiliated medical group and national diagnostic lab partnerships. This end-to-end digital care experience positions them to efficiently deliver branded GLP-1 therapies at scale.
From a technology perspective, this integration creates a closed-loop system where consultation, prescription, fulfillment, and ongoing support all occur within a single platform. The result is a more coherent patient experience with fewer abandonment points.
LifeMD's approach of combining virtual consultations, lab testing, diet and lifestyle support, and medication access within one tech-enabled platform demonstrates how digital health companies are evolving beyond simple telemedicine into comprehensive virtual care providers.
This integration illustrates how digital health platforms can reduce barriers to care by simplifying complex healthcare journeys. For patients navigating weight management, this streamlined approach eliminates the need to coordinate between multiple providers and pharmacies—a significant advantage in patient acquisition and retention.
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform.
LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single, tech-enabled platform. The addition of direct access to Wegovy® through NovoCare® Pharmacy enhances LifeMD’s ability to support patients with a brand-name GLP-1 option at a recently reduced self-pay cost of
“Working with NovoCare® Pharmacy represents a meaningful step forward for LifeMD’s weight management program,” said Justin Schreiber, Chairman and CEO of LifeMD. “By embedding direct access to Wegovy® via NovoCare® Pharmacy into our platform, we’re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD’s position as a leader in delivering comprehensive, technology-enabled obesity care. With this offering, we’ve taken another important step in delivering on our promise of reducing friction in the patient journey—ensuring more patients can access life-changing medications like Wegovy® without unnecessary delays or barriers.”
This offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options. With an end-to-end digital care experience and vertically integrated infrastructure—including a 50-state affiliated medical group and national diagnostic lab partnerships—LifeMD is uniquely positioned to deliver branded GLP-1 therapies at scale.
Wegovy® is the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. Through this offering, all doses of Wegovy® are available in a pen device to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
FAQ
How much does Wegovy cost through LifeMD (LFMD) cash-pay program in 2025?
What services does LifeMD (LFMD) offer in their weight management program?
Can uninsured patients get Wegovy through LifeMD's (LFMD) platform?
What makes LifeMD's (LFMD) Wegovy delivery service different from competitors?
What FDA approvals does Wegovy have for LifeMD (LFMD) patients?
